Ignite Creation Date:
2025-12-24 @ 1:03 PM
Ignite Modification Date:
2025-12-28 @ 5:33 PM
Study NCT ID:
NCT00227461
Status:
UNKNOWN
Last Update Posted:
2021-02-17
First Post:
2005-09-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
Sponsor:
Kessler Foundation
Organization:
Study Overview
Official Title:
Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.
Detailed Description:
In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| none applicable | None | None | View |